4 completed, 1 terminated, 1 unknown. 2 Phase 3, 1 Early Phase 1, 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 1, Unknown 1 |
| Early Phase 1 | 1 | Completed 1 |
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Completed 1 |
Follow Undifferentiated Fallopian Tube Carcinoma: new trials by email Literature Review of Undifferentiated Fallopian Tube Carcinoma trials Research Report on Undifferentiated Fallopian Tube Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Bevacizumab, Cyclophosphamide, Laboratory Biomarker Analysis - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 2 | Completed | Roswell Park Cancer Institute | 40 | 2016-09-01 | 2021-10-06 |
| Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Laboratory Biomarker Analysis, Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Tumor | Early Phase 1 | Completed | Mayo Clinic | 19 | 2014-04-14 | 2025-10-31 |
| Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Behavioral Dietary Intervention, Compliance Monitoring, Counseling - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 3 | Unknown | Gynecologic Oncology Group | 1070 | 2012-06-18 | 2018-02-19 |
| Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Bortezomib, Carboplatin, Laboratory Biomarker Analysis - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 1 | Completed | National Cancer Institute (NCI) | 33 | 2010-04-05 | 2019-08-09 |
| YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis - Fallopian Tube Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Terminated | Gynecologic Oncology Group | 2500 | 2007-09-01 | 2018-05-22 | |
| Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Bevacizumab, Carboplatin, Laboratory Biomarker Analysis - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 3 | Completed | National Cancer Institute (NCI) | 1873 | 2005-09-01 | 2019-07-23 |
Fallopian Tube Neoplasms (6) · Ovarian Neoplasms (5) · Brenner Tumor (4)
Adnexal Diseases (6) · Endocrine System Diseases (6) · Fallopian Tube Diseases (6) · Female Urogenital Diseases (6) · Female Urogenital Diseases and Pregnancy Complications (6) · Genital Diseases (6) · Genital Diseases, Female (6) · Genital Neoplasms, Female (6) · Gonadal Disorders (6) · Neoplasms (6) · Neoplasms by Site (6) · Ovarian Diseases (6) · Urogenital Diseases (6) · Urogenital Neoplasms (6) · Endocrine Gland Neoplasms (5)
Bevacizumab (2) · Carboplatin (2) · Disulfides (2) · Immunoglobulin G (2) · Bortezomib (1) · Counseling (1) · Cyclophosphamide (1) · Early Intervention, Educational (1) · Educational Status (1) · Methods (1) · Paclitaxel (1) · Taxes (1) · pembrolizumab (1)
Gynecologic Oncology Group (2) · National Cancer Institute (NCI) (2) · Mayo Clinic (1) · Roswell Park Cancer Institute (1)
United States (6) · Canada (1) · Japan (1) · South Korea (1)
David Alberts (1) · Don Dizon (1) · Emese Zsiros (1) · Katherine Bell-McGuinn (1) · Matthew S. Block, M.D., Ph.D. (1) · Robert Burger (1)
PMID 21941283, PMID 22204724, PMID 23219660, PMID 26487588, PMID 27394382, PMID 28341300, PMID 29550184, PMID 31216226, PMID 33211063, PMID 35144591, PMID 36252167, PMID 36608382, PMID 37185961, PMID 39638782
U10CA027469 (3), U10CA180868 (3), P50CA136393 (1), U10CA101165 (1), U10CA180830 (1), UG1CA189867 (1)